IRIXNasdaqElectromedical & Electrotherapeutic ApparatusFiscal year ends January 3
IRIDEX CORP
Financials through Q2 FY2026, quarter ended Jul 4, 2026Last filing: 10-Q on Aug 18, 2026
$0.77−0.04 (-5.48%)
Close on Oct 19, 2026
- Market cap
- $13.41M
- P/E (TTM)
- –
- Dividend yield
- –
IRIDEX CORP revenue by segment
By business segment
By product or service
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Retina | $30.28M | $27.83M | $29.45M | $31.66M | $31.11M | $18.09M | $22.88M | $23.71M | – | – | 57.5% | +8.8% |
| Cyclo G6 | $13.84M | $12.70M | $13.46M | $14.69M | $13.95M | $11.27M | – | – | – | – | 26.3% | +9.0% |
| Other | $8.55M | $8.15M | $8.96M | $10.62M | $8.85M | $6.99M | $7.50M | $7.08M | – | – | 16.2% | +5.0% |
| Service Contract Revenues | $1.30K | $1.40K | $1.53M | $1.51M | $1.39M | $1.26M | $1.36M | $1.32M | $1.16M | – | 0.0% | -7.1% |
| Systems | – | – | – | – | – | – | – | $20.01M | $19.70M | – | – | – |
| Recurring Revenues | – | – | – | – | – | – | – | $22.59M | $21.89M | – | – | – |
| G6 | – | – | – | – | – | $11.27M | $13.07M | $11.81M | – | – | – | – |
By region
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| United States | $23.21M | $22.69M | $26.05M | $29.18M | $24.95M | $19.31M | $22.27M | $22.10M | $23.02M | $25.17M | 44.1% | +2.3% |
| Europe, Middle East and Africa | $14.39M | $11.82M | $13.52M | $13.80M | $13.97M | – | – | – | – | – | 27.3% | +21.7% |
| Asia/Pacific Rim | $12.95M | $11.95M | $10.23M | $10.93M | $12.44M | $7.06M | $8.43M | $8.17M | $8.16M | $8.62M | 24.6% | +8.4% |
| Americas, excluding the U.S. | $2.12M | $2.21M | $2.06M | $3.06M | $2.54M | $1.97M | $2.86M | $2.59M | $2.32M | – | 4.0% | -3.8% |
| Europe | – | – | – | – | $13.57M | $8.01M | $9.89M | $9.74M | $8.10M | $9.57M | – | – |
| Rest of Americas | – | – | – | – | – | – | – | – | $2.32M | $2.80M | – | – |
From the segment and revenue-disaggregation notes of Iridex's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.